Site Search     
  A CHR Trial Investigation Outcomes of Exercise Training
  A Pull-Push Strategy for Lymphoma Immunotherapy
  Altered CD8+ T Cell Compartment in SLE Patients
  Biology and Diagnosis of HNPCC
  Center for Lupus Research
  CHAVI Innate Discovery
  Colon Cancer Prevention Program Project
  Consortium to Analyze Tolerogenic Dendritic Cells in Respiratory Syncytial Virus Infection
  Development of Neonatal Oxygen Therapy Information System to Support Oximetry Targets in Newborn Intensive Care Units
  Effect of S-adenosylmethionine on Blood Homocysteine
Functional MR in Ischemic Cardiomyopathy
  Human Dendritic Cells and In Vivo Immunity to Biothreat
  Improving the Efficacy of Dendritic Cell Vaccines
  JC Virus and Tumor Formation in the Human Colon
  New Predictors of SLE Disease Activity
  NIAID Cooperative Center Luminex Facility
  Rural Hospital Collaborative for Excellence Using IT
  Targeting Langerhans Cells for Therapeutic Vaccination in Breast Cancer
  Transcriptional Signatures for Diagnosis of Different Spectra of Mycobacterium tuberculosis Infection and Characterization of the Immune Response during Latency or Active Disease
  Subpopulations of Human Dendritic Cells
  Use of Microarrays to Understand Systemic Arthritis
Functional MR in Ischemic Cardiomyopathy
Grant Number: 5R01HL072430-03
PI: Paul A. Grayburn
ICD: National Heart, Lung, and Blood Institute
IRG: ZHL1
Project Start: September 20, 2002
Project End: December 31, 2007
 
Abstract:

Functional mitral regurgitation (MR) is a common complication of ischemic heart disease. Two large clinical trials confirmed an adverse effect of functional MR on survival after a heart attack. However, studies in heart failure are small and mainly limited to patients with nonischemic cardiomyopathy. Recent animal studies have challenged the traditional concept that functional MR is a consequence of mitral annular dilation, instead suggesting that functional MR is due to leaflet tethering by outward expansion of the left ventricular wall (i.e. LV remodeling). This has critical implications regarding the correct surgical approach to correcting functional MR. To date, no large prospective studies have examined the mechanism(s) of functional MR in ischemic cardiomyopathy, nor has the interaction between mechanism and prognosis been explored. This is a crucial knowledge gap because 1) 70% of heart failure cases are caused by ischemic heart disease, and 2) functional MR occurs in around 60% of patients with ischemic cardiomyopathy. This proposal aims to fill these gaps by defining the mechanism(s) of functional MR by transesophageal echocardiography in a large clinical trial of patients with ischemic cardiomyopathy. The following specific aims will be addressed: Aim 1: To define the mechanism(s) of functional MR in ischemic cardiomyopathy; Aim 2: To define the effect of therapy on mechanism and severity of functional MR; Aim 3: To evaluate the effect of functional MR on prognosis is ischemic cardiomyopathy; Aim 4: To evaluate the effect of myocardial viability on functional MR and its response to treatment. We propose to accomplish these aims as a ancillary study to the Surgical Treatment of Ischemic Heart Failure (STICH) Trial. The STICH Trial will compare surgical revascularization versus medical therapy for treatment of heart failure in 2800 patients with ischemic cardiomyopathy, and therefore affords a unique opportunity to investigate the mechanism(s) of functional MR. Despite its known clinical utility of assessing the mechanism and severity of MR, TEE is not currently included in STICH.